The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis

Çolak, Ayfer; Zeytinli Aksit, Merve; Erdinç Gündüz, Nihan; dikici, aylin; SERTPOYRAZ, FİLİZ MERYEM

doi:10.14744/nci.2020.23590

The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis

Filiz Meryem SERTPOYRAZ, (Sağlık Bilimleri Üniversitesi, İzmir Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, İzmir, Türkiye)

Ayfer ÇOLAK, (Sağlık Bilimleri Üniversitesi, İzmir Eğitim ve Araştırma Hastanesi, Biyokimya Anabilim Dalı, İzmir, Türkiye)

Aylin DİKİCİ, (Sağlık Bilimleri Üniversitesi, İzmir Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, İzmir, Türkiye)

Onur ENGİN, (Sağlık Bilimleri Üniversitesi, İzmir Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, İzmir, Türkiye)

Merve ZEYTİNLİ (Sağlık Bilimleri Üniversitesi, İzmir Eğitim ve Araştırma Hastanesi, Biyokimya Anabilim Dalı, İzmir, Türkiye)

İstanbul Kuzey Klinikleri

2 0

Yıl: 2021 Cilt: 8 Sayı: 1 Sayfa Aralığı: 42 - 48 Metin Dili: İngilizce DOI: 10.14744/nci.2020.23590 İndeks Tarihi: 19-06-2021

The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis

Öz:

OBJECTIVE: Recent studies have implicated increased oxidative stress in the pathogenesis of Ankylosing spondylitis (AS). Ischemia-modified albumin (IMA), an altered form of albumin, increases oxidative stress. This study aimed to investigate the relationship between IMA levels and other indicators of disease severity in AS.METHODS: This study included 63 AS patients and 48 healthy controls. Patients were examined for serum lipid profile, C-reactive protein (CRP), complete blood count, Bath Ankylosing Spondylitis Disease Activity Index, human leukocyte antigen (HLA) B27, and treatment regimen. They were categorized based on disease activity, HLA-B27 status, and the drug treatment and compared for IMA levels.RESULTS: The patients had significantly higher IMA levels than controls (p=0.020); among patients, the levels were higher in those with active disease (p=0.001) and positively correlated with the CRP levels. No significant difference was found between the IMA levels of the patients with different HLA-B27 status or treatment method.CONCLUSION: The IMA levels were higher in patients than controls and further increased in patients with active AS. IMA was associated with disease activity and can be used as an inflammatory marker in AS. More comprehensive future studies with a larger sample size may help understand the relationship in greater detail.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61 Suppl 3:iii8–18.
2. Bodur H, Ataman S, Buğdaycı DS, Rezvani A, Nas K, Uzunca K, et al; Türkiye Romatizma Araştırma ve Savaş Derneği [TRASD] (Turkish League Against Rheumatism) Ankylosing Spondylitis [AS] Study Group. Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. Rheumatol Int 2012;32:169–76.
3. Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010;6:399–405.
4. Smallwood MJ, Nissim A, Knight AR, Whiteman M, Haigh R, Winyard PG. Oxidative stress in autoimmune rheumatic diseases. Free Radic Biol Med 2018;125:3–14.
5. Najim RA, Sharquie KE, Abu-Raghif AR. Oxidative stress in patients with Behcet’s disease: I correlation with severity and clinical parameters. J Dermatol 2007;34:308–14.
6. Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 2010;20:34–9.
7. Shah D, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 2014;21:23.
8. Péter I, Jagicza A, Ajtay Z, Kiss I, Németh B. Psoriasis and oxidative stress. [Article in Hu]. Orv Hetil 2016;157:1781–5.
9. Gupta L, Bhattacharya S, Aggarwal A. Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis. Clin Rheumatol 2018;37:1401–5.
10. Biasi D, Carletto A, Caramaschi P, Bellavite P, Andrioli G, Caraffi M, et al. Neutrophil functions, spondylarthropathies and HLA-B27: a study of 43 patients. Clin Exp Rheumatol 1995;13:623–7.
11. Piva SJ, Duarte MM, Da Cruz IB, Coelho AC, Moreira AP, Tonello R, et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011;44:345–7.
12. Uslu AU, Kucuk A, Balta S, Ozturk C, Arslan S, Tekin L, et al. The relation between ischemia modified albumin levels and carotid intima media thickness in patients with rheumatoid arthritis. Int J Rheum Dis 2019;22:32–7.
13. Türkön H, Gökmen F, Çakir DÜ, Sehitoğlu MH, Reşorlu H, Döner D, et al. Increased Levels of Serum Ischemia Modified Albumin in Patients with Ankylosing Spondylitis. Clin Lab 2016;62:645–9.
14. Rezvani A, Bodur H, Ataman S, Kaya T, Buğdaycı DS, Demir SE, et al. Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis. Mod Rheumatol 2014;24:651–6.
15. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311–5.
16. Au YL, Wong WS, Mok MY, Chung HY, Chan E, Lau CS. Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS? Clin Rheumatol 2014;33:1127–34.
17. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003;11:747–55.
18. Järvinen TA, Moilanen T, Järvinen TL, Moilanen E. Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediators Inflamm 1995;4:107–11.
19. Altan N, Dincel A, Koca C. Diabetes mellitus and oxidative stress. Turk J Biochem 2006,31:51–6.
20. Zurawska-Płaksej E, Grzebyk E, Marciniak D, Szymańska-Chabowska A, Piwowar A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J Endocrinol Invest 2014;37:819– 27.
21. Mehmetoğlu I, Kurban S, Yerlikaya FH, Polat H. Obesity is an independent determinant of ischemia-modified albumin. Obes Facts 2012;5:700–9.
22. Aydin O, Ellidag HY, Eren E, Kurtulus F, Yaman A, Yılmaz N. Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Med (Zagreb) 2014;24:383–9.
23. Mastella AK, Moresco RN, da Silva DB, Becker AM, Duarte MM, Giovelli LL, et al. Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. Biomed Pharmacother 2009;63:762–6.
24. Kılıç S, Işık S, Hiz MM, Çakır DÜ, Türkön H, Cevizci S, et al. The ischemia modified albumin and mean platelet volume levels in patients with Behçet’s disease. Postepy Dermatol Alergol 2016;33:345–8.
25. Leitemperguer MR, Tatsch E, Kober H, De Carvalho JA, Moresco RN, Da Silva JE. Assessment of ischemia-modified albumin levels in patients with rheumatoid arthritis. Clin Lab 2014;60:1065–70.
26. Gökmen F, Türkön H, Akbal A. The relationship between inflammatory parameters and atherosclerosis with ischemic modified albumin levels in Sjögren syndrome. Selçuk Tıp Derg 2015,31:20–3.
27. Solmaz D, Kozacı D, Sarı İ, Taylan A, Önen F, Akkoç N, et al. Oxidative stress and related factors in patients with ankylosing spondylitis. Eur J Rheumatol 2016;3:20–4.
28. Wang L, Gao L, Jin D, Wang P, Yang B, Deng W, et al. The Relationship of Bone Mineral Density to Oxidant/Antioxidant Status and Inflammatory and Bone Turnover Markers in a Multicenter Cross-Sectional Study of Young Men with Ankylosing Spondylitis. Calcif Tissue Int 2015;97:12–22.
29. Monti S, Todoerti M, Codullo V, Favalli EG, Biggioggero M, Becciolini A, et al. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol 2018;28:542–9.
30. Altan L. Current treatment options in ankylosing spondylitis. Turk J Phys Med Rehab 2005,51:33–9.
31. Almodóvar R, Ríos V, Ocaña S, Gobbo M, Casas ML, Zarco-Montejo P, et al. Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis. Clin Rheumatol 2014;33:237–41.
32. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol. 2014;57:28–37.
33. Karataş Z, Baysal T, Şap F, Alp H, Mehmetoğlu I. Increased ischaemia- modified albumin is associated with inflammation in acute rheumatic fever. Cardiol Young 2014;24:430–6.
34. Harman E, Sayarlıoglu M, Harman M, Sayarlıoglu H. The evaluation of coagulation parameters and vessel involvement in Behcet’ s disease. A clinical experience of Behcet’ s disease: study of 152 cases. Acta Med Iran 2013;51:215–23.
35. Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol 2014;57:44–51.
36. Sampaio-Barros PD, Conde RA, Bonfiglioli R, Bértolo MB, Samara AM. Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int 2006;26:1143–6.
37. Kocabaş V, Kocabaş H, Başaralı MK, Sezer I, Kaçar C,et al. The level of serum oxidant-antioxidant in patients with ankylosing spondylitis. Selçuk Üniv Tıp Derg 2010,26:79–83.
38. Yazici C, Köse K, Calis M, Kuzugüden S, Kirnap M. Protein oxidation status in patients with ankylosing spondylitis. Rheumatology (Oxford) 2004;43:1235–9.
39. Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:73–80.
40. Karkucak M, Capkin E, Alver A, Akyuz A, Kiris A, Ak E, et al. The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Clin Rheumatol 2010;29:303–7.

APA	SERTPOYRAZ F, Çolak A, dikici a, Erdinç Gündüz N, Zeytinli Aksit M (2021). The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. , 42 - 48. 10.14744/nci.2020.23590
Chicago	SERTPOYRAZ FİLİZ MERYEM,Çolak Ayfer,dikici aylin,Erdinç Gündüz Nihan,Zeytinli Aksit Merve The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. (2021): 42 - 48. 10.14744/nci.2020.23590
MLA	SERTPOYRAZ FİLİZ MERYEM,Çolak Ayfer,dikici aylin,Erdinç Gündüz Nihan,Zeytinli Aksit Merve The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. , 2021, ss.42 - 48. 10.14744/nci.2020.23590
AMA	SERTPOYRAZ F,Çolak A,dikici a,Erdinç Gündüz N,Zeytinli Aksit M The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. . 2021; 42 - 48. 10.14744/nci.2020.23590
Vancouver	SERTPOYRAZ F,Çolak A,dikici a,Erdinç Gündüz N,Zeytinli Aksit M The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. . 2021; 42 - 48. 10.14744/nci.2020.23590
IEEE	SERTPOYRAZ F,Çolak A,dikici a,Erdinç Gündüz N,Zeytinli Aksit M "The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis." , ss.42 - 48, 2021. 10.14744/nci.2020.23590
ISNAD	SERTPOYRAZ, FİLİZ MERYEM vd. "The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis". (2021), 42-48. https://doi.org/10.14744/nci.2020.23590

APA	SERTPOYRAZ F, Çolak A, dikici a, Erdinç Gündüz N, Zeytinli Aksit M (2021). The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. İstanbul Kuzey Klinikleri, 8(1), 42 - 48. 10.14744/nci.2020.23590
Chicago	SERTPOYRAZ FİLİZ MERYEM,Çolak Ayfer,dikici aylin,Erdinç Gündüz Nihan,Zeytinli Aksit Merve The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. İstanbul Kuzey Klinikleri 8, no.1 (2021): 42 - 48. 10.14744/nci.2020.23590
MLA	SERTPOYRAZ FİLİZ MERYEM,Çolak Ayfer,dikici aylin,Erdinç Gündüz Nihan,Zeytinli Aksit Merve The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. İstanbul Kuzey Klinikleri, vol.8, no.1, 2021, ss.42 - 48. 10.14744/nci.2020.23590
AMA	SERTPOYRAZ F,Çolak A,dikici a,Erdinç Gündüz N,Zeytinli Aksit M The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. İstanbul Kuzey Klinikleri. 2021; 8(1): 42 - 48. 10.14744/nci.2020.23590
Vancouver	SERTPOYRAZ F,Çolak A,dikici a,Erdinç Gündüz N,Zeytinli Aksit M The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis. İstanbul Kuzey Klinikleri. 2021; 8(1): 42 - 48. 10.14744/nci.2020.23590
IEEE	SERTPOYRAZ F,Çolak A,dikici a,Erdinç Gündüz N,Zeytinli Aksit M "The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis." İstanbul Kuzey Klinikleri, 8, ss.42 - 48, 2021. 10.14744/nci.2020.23590
ISNAD	SERTPOYRAZ, FİLİZ MERYEM vd. "The relationship of ischemia-modified albumin levels to disease activity scores and HLA-B27 in patients with ankylosing spondylitis". İstanbul Kuzey Klinikleri 8/1 (2021), 42-48. https://doi.org/10.14744/nci.2020.23590